Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RARE Ultragenyx Pharmaceutical Inc

盘后交易 09-03 18:20:44 EDT

14.85

-11.68

-44.03%

盘后14.82

-0.03-0.20%

18:20 EDT

最高15.00	最低13.81	成交量2,708万
今开14.00	昨收26.53	日振幅4.49%
总市值14.60亿	流通市值11.99亿	总股本9,832万
成交额3.94亿	换手率33.55%	流通股本8,072万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RARE","market":"US","secType":"STK","nameCN":"Ultragenyx Pharmaceutical Inc","latestPrice":14.85,"timestamp":1788465600000,"preClose":26.53,"halted":0,"volume":27081553,"hourTrading":{"tag":"盘后","latestPrice":14.8201,"preClose":14.85,"latestTime":"18:20 EDT","volume":227512,"amount":3377308.936872,"timestamp":1788474015758,"change":-0.0299,"changeRate":-0.002013,"amplitude":0.012795},"delay":0,"changeRate":-0.4402563136072371,"floatShares":80715600,"shares":98317221,"eps":-5.827946,"marketStatus":"盘后交易","change":-11.68,"latestTime":"09-03 18:20:44 EDT","open":14,"high":15,"low":13.81,"amount":394405501.064966,"amplitude":0.044855,"askPrice":14.84,"askSize":9,"bidPrice":14.81,"bidSize":590,"shortable":0,"etf":0,"ttmEps":-5.827946,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1788480000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":26.53,"preHourTrading":{"tag":"盘前","latestPrice":13.9,"preClose":26.53,"latestTime":"09:29 EDT","volume":1308689,"amount":18514633.132074,"timestamp":1788442199999,"change":-12.63,"changeRate":-0.476065,"amplitude":0.05277},"postHourTrading":{"tag":"盘后","latestPrice":14.8201,"preClose":14.85,"latestTime":"18:20 EDT","volume":227512,"amount":3377308.936872,"timestamp":1788474015758,"change":-0.0299,"changeRate":-0.002013,"amplitude":0.012795},"volumeRatio":9.860228,"optionData":{"bulkOrders":[{"symbol":"RARE","call":true,"expireDate":1799989200000,"strike":"15.0","timestamp":1788451757468,"price":2.8,"volume":4000,"amount":1120000,"type":"+"},{"symbol":"RARE","call":false,"expireDate":1792123200000,"strike":"27.5","timestamp":1788445693188,"price":12.71,"volume":1730,"amount":2198830,"type":"-"}]},"impliedVol":0.7709,"impliedVolPercentile":0.6627},"requestUrl":"/m/hq/s/RARE","defaultTab":"news","newsList":[{"id":"1180525046","title":"美股盘前｜美债收益率回落，美股股指期货上涨；绩优股Snowflake盘前飙23%、Netskope涨12%，博通绩后跌超3%、维多利亚的秘密跌逾17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180525046","media":"老虎资讯综合","labels":["AIColumn"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180525046?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:35","pubTimestamp":1788438939,"startTime":"0","endTime":"0","summary":"01 股市截至9月3日，美股三大期指涨跌不一，市场情绪偏谨慎。9月3日美元指数下降0.4309%，报99.14。","market":"sg","thumbnail":"https://static.tigerbbs.com/1d6a4572b675796b315e560ea7fe3401","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1d6a4572b675796b315e560ea7fe3401"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"AIColumn","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","WOOF","CPB","ESmain","YMmain","NTSK","VSXY","AGX","RARE"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1124499300","title":"Ultragenyx Pharmaceutical治疗罕见病Angelman综合征的药物在后期试验中失败","url":"https://stock-news.laohu8.com/highlight/detail?id=1124499300","media":"老虎资讯综合","labels":["dataReport"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124499300?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:34","pubTimestamp":1788424478,"startTime":"0","endTime":"0","summary":"生物技术公司  $Ultragenyx Pharmaceutical Inc$ 表示，其治疗Angelman综合征的实验性疗法在一项大型3期试验中与模拟治疗相比未显示出获益。该药物GTX-102在早期试验中曾显示出显著效果，给受这种毁灭性疾病影响的家庭带来了希望。这一消息对Ultragenyx的业务也是一个重大打击。尽管该公司有多种获批药物，但它们大多针对超罕见疾病，投资者一直指望这款Angelman综合征药物成为公司实现盈利的途径。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Ultragenyx Pharmaceutical治疗罕见病Angelman综合征的药物在后期试验中失败","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162487658","title":"Ultragenyx制药宣布评估Apazunersen项目并实施重大费用削减计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1162487658","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162487658?lang=zh_cn&edition=full","pubTime":"2026-09-03 04:03","pubTimestamp":1788379416,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical——这家专注于罕见病药物研发的生物制药公司，近日对外宣布，将对其Apazunersen项目进行全面评估，同时着手推行一系列意义深远的费用缩减措施。\n这一战略调整，无疑透露出公司在管线优化与资源分配上的深思熟虑。对于Apazunersen这一在研项目，公司显然意在通过严谨的审视，为其后续走向定夺方向。\n与此同时，费用削减计划的实施，也昭示着公司正在积极应对当前的经济环境，力求在研发投入与财务稳健之间寻求更为精准的平衡。此举或将对公司未来的运营格局产生重要影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192232987","title":"Ultragenyx宣布Genglycos™（亦称DTX401）AAV基因疗法治疗GSD Ia的96周随机安慰剂对照交叉试验成功发表于《遗传代谢病杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=1192232987","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192232987?lang=zh_cn&edition=full","pubTime":"2026-09-02 04:07","pubTimestamp":1788293247,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical今日宣布，其针对Ia型糖原贮积病的AAV基因疗法Genglycos所开展的一项长达96周的随机、安慰剂对照、交叉设计临床试验，其研究成果已正式发表于权威期刊《遗传代谢病杂志》。该项研究历时近两年，采用严谨的双盲、随机、安慰剂对照方法，并在后期阶段引入交叉治疗设计，旨在全面评估Genglycos在GSD Ia患者群体中的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171211170","title":"Ultragenyx罕见代谢病基因疗法获FDA批准，盘前股价飙升8.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171211170","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171211170?lang=zh_cn&edition=full","pubTime":"2026-08-20 19:04","pubTimestamp":1787223856,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical（股票代码：RARE）周三盘前交易时段股价大幅攀升8.6%，此前该公司宣布其针对罕见代谢紊乱的基因疗法已获得美国食品药品监督管理局（FDA）的正式批准。这一里程碑式的进展，无疑为这家生物制药公司注入了强劲的市场信心。该疗法专门用于治疗一种罕见的遗传性代谢疾病，为长期缺乏有效治疗方案的患者群体带来了新的希望。市场对此消息反应热烈，投资者情绪高涨，推动股价在常规交易开始前即出现显著上涨。分析人士指出，此次获批不仅有望为Ultragenyx打开新的收入渠道，也可能巩固其在基因治疗细分领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198454665","title":"Ultragenyx制药：Genglycos将经由全国合格治疗中心网络供应","url":"https://stock-news.laohu8.com/highlight/detail?id=1198454665","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198454665?lang=zh_cn&edition=full","pubTime":"2026-08-20 05:24","pubTimestamp":1787174659,"startTime":"0","endTime":"0","summary":"Ultragenyx制药公司宣布，其产品Genglycos将通过一个覆盖全国的合格治疗中心网络正式投放市场。这一举措意味着，患者有望在更广泛的医疗网点获得该药物，从而显著提升治疗可及性。据悉，这一网络体系的构建旨在确保药物配送的专业性与规范化，并有望为罕见病治疗领域带来新的格局。Ultragenyx Pharmaceutical Inc作为一家专注创新疗法的生物制药企业，其此次布局备受业界关注。通过这一战略渠道，Genglycos的供应将更为高效有序，并更好地服务于目标患者群体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134415890","title":"里程碑时刻！美国FDA批准Ultragenyx基因疗法Genglycos™上市——全球首款直击Ia型糖原贮积症病根的治疗方案问世","url":"https://stock-news.laohu8.com/highlight/detail?id=1134415890","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134415890?lang=zh_cn&edition=full","pubTime":"2026-08-20 05:22","pubTimestamp":1787174530,"startTime":"0","endTime":"0","summary":"重大利好消息传来！Ultragenyx Pharmaceutical今日宣布，其重磅基因疗法Genglycos已正式获得美国食品药品监督管理局的上市批准。这不仅是一个产品的获批，更是医学史上的一座里程碑——Genglycos作为全球首款旨在根治Ia型糖原贮积症潜在病因的获批疗法，为无数患者家庭点燃了前所未有的希望之火。回望过去，GSDIa患者长期面临的是对症治疗带来的沉重负担与无尽痛苦。随着Genglycos正式走向临床，其实际应用效果与长期安全性，也将成为医学界持续关注的焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150335631","title":"Ultragenyx与Bri就Dojolvi专利诉讼与Esjay Pharma达成和解——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1150335631","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150335631?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:39","pubTimestamp":1786451977,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical（RARE）及其关联方Bri，已与Esjay Pharma就Dojolvi相关专利诉讼达成和解。这一消息源自美国证券交易委员会（SEC）的官方文件披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176375683","title":"Ultragenyx制药：2033年起将向Esjay授予Dojolvi仿制药销售的非独家、免版税许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1176375683","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176375683?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:37","pubTimestamp":1786451830,"startTime":"0","endTime":"0","summary":"Ultragenyx制药公司宣布，自2033年1月1日起，将向Esjay授予一项非独家、免版税许可，允许其销售Dojolvi的仿制药版本。这一举措标志着该公司在管线药物专利布局与市场准入策略上迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657550099","title":"USA RARE EARTH涨幅扩大至8.9%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657550099","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657550099?lang=zh_cn&edition=full","pubTime":"2026-08-05 00:28","pubTimestamp":1785860926,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","RARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154584198","title":"Calidi Biotherapeutics任命前基因泰克/罗氏与Celgene高管Corsee Sanders博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1154584198","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154584198?lang=zh_cn&edition=full","pubTime":"2026-06-23 20:03","pubTimestamp":1782216238,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics宣布，任命在生物技术领域拥有丰富经验的前基因泰克/罗氏及Celgene公司高管Corsee Sanders博士加入其董事会。此项人事任命旨在强化公司的战略指导与治理能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEGN","BK4585","BK4588","BK4139","CLDI","RARE","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106153135","title":"Ultragenyx 根据纳斯达克上市规则授予员工入职激励股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1106153135","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106153135?lang=zh_cn&edition=full","pubTime":"2026-06-20 04:30","pubTimestamp":1781901039,"startTime":"0","endTime":"0","summary":"专注于研发和商业化罕见及超罕见疾病创新疗法的生物制药公司 Ultragenyx Pharmaceutical Inc. 今日宣布，根据纳斯达克上市规则 5635，公司已向 15 名新入职的非高管人员授予了 44,409 份公司普通股限制性股票单位。该奖项由公司董事会薪酬委员会批准，依据 Ultragenyx 员工入职激励计划授予，授予日期为 2026 年 6 月 16 日，旨在作为吸引新员工加入公司的重要激励措施。Ultragenyx 的战略立足于高效、经济的药物开发，目标是以最快的速度向患者提供安全有效的疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139455884","title":"Ultragenyx宣布美国FDA接受UX111 AAV基因疗法BLA重新提交，用于治疗A型圣菲利波综合征（MPS IIIA）","url":"https://stock-news.laohu8.com/highlight/detail?id=1139455884","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139455884?lang=zh_cn&edition=full","pubTime":"2026-04-02 20:32","pubTimestamp":1775133132,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical（纳斯达克代码：RARE）近日宣布，美国食品药品监督管理局（FDA）已正式受理其针对UX111 AAV基因疗法的生物制品许可申请（BLA）重新提交。该疗法旨在治疗A型圣菲利波综合征（又称黏多糖贮积症IIIA型，MPS IIIA）。\n此次BLA重新提交标志着公司在推进该罕见病治疗领域的重要进展。UX111作为一种创新基因疗法，通过腺相关病毒载体递送功能性基因，有望为MPS IIIA患者提供新的治疗选择。\nFDA的受理决定将启动相关审评流程，后续进展备受市场关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160853916","title":"Ultragenyx宣布FDA批准UX016研究性新药申请，用于治疗GNE肌病","url":"https://stock-news.laohu8.com/highlight/detail?id=1160853916","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160853916?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:32","pubTimestamp":1774873951,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical（纳斯达克代码：RARE）今日宣布，美国食品药品监督管理局（FDA）已批准其研究性新药UX016的临床试验申请。UX016是一种唾液酸前体药物，旨在用于治疗GNE肌病，这是一种罕见的遗传性肌肉疾病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176626417","title":"Ultragenyx制药DTx301第36周24小时血浆氨水平较安慰剂降低18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176626417","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176626417?lang=zh_cn&edition=full","pubTime":"2026-03-12 20:33","pubTimestamp":1773318808,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical（纳斯达克代码：RARE）宣布，其创新疗法DTx301在治疗周期第36周时展现出显著疗效——患者24小时血浆氨水平较安慰剂组平均降低18%。该数据来自针对尿素循环障碍患者的二期临床试验，证实了DTx301在持续控制血氨方面的临床价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172387552","title":"Ultragenyx Pharmaceutical Inc：DTX301组高氨血症危象减少且无死亡病例，优于安慰剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1172387552","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172387552?lang=zh_cn&edition=full","pubTime":"2026-03-12 20:33","pubTimestamp":1773318804,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical Inc公布的研究数据显示，与安慰剂组相比，其试验性疗法DTX301在治疗期间显著减少了高氨血症危象的发生次数，且该组未出现任何死亡病例。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102014175","title":"Ultragenyx Pharmaceutical Inc：治疗负担减轻次要终点数据预计2027年上半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1102014175","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102014175?lang=zh_cn&edition=full","pubTime":"2026-03-12 20:33","pubTimestamp":1773318803,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical Inc 近日透露，其关于减轻治疗负担的次要终点数据，预计将在2027年上半年公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187091525","title":"Ultragenyx公布DTX301 AAV8基因疗法治疗鸟氨酸氨甲酰基转移酶缺乏症三期研究36周积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1187091525","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187091525?lang=zh_cn&edition=full","pubTime":"2026-03-12 20:32","pubTimestamp":1773318743,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical Inc（简称Ultragenyx）近日宣布，其针对鸟氨酸氨甲酰基转移酶（OTC）缺乏症研发的DTX301 AAV8基因疗法，在三期临床研究中取得了36周的积极数据。这一进展标志着该基因疗法在长期疗效与安全性方面展现出令人鼓舞的结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514693738","title":"Ultragenyx Pharmaceutical Inc.盘中异动 快速拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514693738","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514693738?lang=zh_cn&edition=full","pubTime":"2025-02-27 02:31","pubTimestamp":1740594704,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日02时31分，Ultragenyx Pharmaceutical Inc.股票出现异动，股价快速上涨5.02%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为0.53%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。Mepsevii 适用于儿童和成人患者，用于治疗粘多糖贮积症 VII。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227023144a2552d5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227023144a2552d5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512654151","title":"Ultragenyx Pharmaceutical Inc.盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512654151","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512654151?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:42","pubTimestamp":1739889762,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时42分，Ultragenyx Pharmaceutical Inc.股票出现波动，股价急速拉升5.00%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体涨幅为0.55%。其相关个股中，Solid Biosciences Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Pulmatrix, Inc.涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为303.06%、107.94%、86.68%，振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Conduit Pharmaceuticals Inc.、Pulmatrix, Inc.，振幅分别为34.04%、26.83%、23.16%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182242429889ff3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182242429889ff3e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ultragenyx.com","stockEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.0604},{"period":"3month","weight":0.1381},{"period":"6month","weight":0.2485},{"period":"1year","weight":-0.1717},{"period":"ytd","weight":0.1535}],"compareEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":0.0099},{"period":"3month","weight":0.0107},{"period":"6month","weight":0.138},{"period":"1year","weight":0.1951},{"period":"ytd","weight":0.1221}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ultragenyx Pharmaceutical Inc.于2010年4月22日成立，是一家处于发展阶段的生物科技企业，公司随后于2011年6月在特拉华州重新注册成立。公司专注于新型产品的鉴定、收购、开发与商业化，该产品主要用于治疗罕见和极罕见的疾病，产品最初目标是用于治疗严重的，令人衰弱的代谢基因类疾病。公司目前用于治疗遗传性包涵体肌病患者的缓释唾液酸正处于临床试验第二阶段，该疾病是一种渐进式的肌肉萎缩疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.017448},{"month":2,"riseRate":0.538462,"avgChangeRate":0.064996},{"month":3,"riseRate":0.384615,"avgChangeRate":-0.059821},{"month":4,"riseRate":0.384615,"avgChangeRate":0.018302},{"month":5,"riseRate":0.384615,"avgChangeRate":0.024893},{"month":6,"riseRate":0.769231,"avgChangeRate":0.090343},{"month":7,"riseRate":0.384615,"avgChangeRate":-0.019129},{"month":8,"riseRate":0.615385,"avgChangeRate":0.033366},{"month":9,"riseRate":0.307692,"avgChangeRate":-0.046583},{"month":10,"riseRate":0.25,"avgChangeRate":-0.056376},{"month":11,"riseRate":0.5,"avgChangeRate":0.037007},{"month":12,"riseRate":0.583333,"avgChangeRate":0.015792}],"exchange":"NASDAQ","name":"Ultragenyx Pharmaceutical Inc","nameEN":"Ultragenyx Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ultragenyx Pharmaceutical Inc(RARE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ultragenyx Pharmaceutical Inc,RARE,Ultragenyx Pharmaceutical Inc股票,Ultragenyx Pharmaceutical Inc股票老虎,Ultragenyx Pharmaceutical Inc股票老虎国际,Ultragenyx Pharmaceutical Inc行情,Ultragenyx Pharmaceutical Inc股票行情,Ultragenyx Pharmaceutical Inc股价,Ultragenyx Pharmaceutical Inc股市,Ultragenyx Pharmaceutical Inc股票价格,Ultragenyx Pharmaceutical Inc股票交易,Ultragenyx Pharmaceutical Inc股票购买,Ultragenyx Pharmaceutical Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ultragenyx Pharmaceutical Inc(RARE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}